Biden admin rejects GM’s warning that US emissions rules will be costly
By David Shepardson WASHINGTON (Reuters) -General Motors warned the Biden administration’s planned changes to vehicle emissions rules could cost the…
Uncategorized
Intel results boost chip stocks on optimism PC market slump is ending
(Corrects company name to TSMC in paragraph 7) (Reuters) -Intel shares surged 7% on Friday, a day after the chipmaker’s…
Exxon profits slump 56%, joins global peers in energy price hit
By Sabrina Valle HOUSTON (Reuters) -Exxon Mobil’s <XOM.N> second-quarter profit dropped 56% and fell short of Wall Street expectations, the…
Chipmakers signal supply glut easing but demand recovery still slow
By Joyce Lee SEOUL (Reuters) -From Intel to Samsung, global chipmakers are celebrating the beginning of the end of a…
Shipping group CMA CGM braced for weaker profit before demand picks up in 2024
PARIS (Reuters) – French shipping group CMA CGM expects container freight demand to improve from next year but the group’s…
Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio
By Manas Mishra and Bhanvi Satija (Reuters) -Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion,…
Laurentian Bank’s shares fall after media report that potential top bidders bowed out
(Reuters) – Laurentian Bank of Canada’s shares fell 9% on Friday after a newspaper reported that the Montreal-based bank was…
AstraZeneca’s rare disease arm in $1 billion deal for Pfizer gene therapies
By Yadarisa Shabong (Reuters) -AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer’s early-stage rare…
Centene aims to enroll back some lost Medicaid members
By Mariam Sunny and Leroy Leo (Reuters) -Centene Corp said on Friday it was working to enroll people back into…
Drugmakers go under the skin, skirting early US Medicare price negotiations
By Michael Erman NEW YORK (Reuters) – Injectable versions of some widely-used cancer drugs including Johnson & Johnson’s blockbuster multiple…